Pfizer, SFJ Pharma To Conduct Phase III Asian Trials Of Carcinoma Drug
This article was originally published in PharmAsia News
U.S.-based SFJ Pharma is to conduct final-phase trials in Asia of Pfizer’s axitinib for renal cell carcinoma.
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.